
## Shinichirio Ueda

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7398949/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of febuxostat on left ventricular diastolic function in patients with asymptomatic hyperuricemia: a sub analysis of the PRIZE Study. Hypertension Research, 2022, 45, 106-115.	2.7	10
2	Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 685-694.	2.4	0
3	Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial. RMD Open, 2022, 8, e002226.	3.8	6
4	Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized) Tj ETQq0 0 ( Journal of Clinical Medicine, 2020, 9, 93.	) rgBT/Ove 2.4	erlock 10 Tf 50
5	Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 2020, 11, 575557.	3.5	7
6	Endosonographic finding of the simultaneous depiction of bile and pancreatic ducts can predict difficult biliary cannulation on endoscopic retrograde cholangiopancreatography. PLoS ONE, 2020, 15, e0235757.	2.5	1
7	Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy. Cardiovascular Diabetology, 2020, 19, 89.	6.8	20
8	Febuxostat does not delay progression of carotid atherosclerosis in patients with asymptomatic hyperuricemia: A randomized, controlled trial. PLoS Medicine, 2020, 17, e1003095.	8.4	57
9	Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy. Journal of Atherosclerosis and Thrombosis, 2020, 29, .	2.0	4
10	<p>Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial</p> . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 13, 4993-5001.	2.4	5
11	Title is missing!. , 2020, 15, e0235757.		0
12	Title is missing!. , 2020, 15, e0235757.		0
13	Title is missing!. , 2020, 15, e0235757.		Ο
14	Title is missing!. , 2020, 15, e0235757.		0
15	Effect of short-term colchicine treatment on endothelial function in patients with coronary artery disease. International Journal of Cardiology, 2019, 281, 35-39.	1.7	52
16	Randomized Evaluation of Anagliptin vs Sitagliptin On low-density lipoproteiN cholesterol in diabetes (REASON) Trial: A 52-week, open-label, randomized clinical trial. Scientific Reports, 2019, 9, 8537.	3.3	12
17	Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: a secondary analysis of the REASON trial. Cardiovascular Diabetology, 2019, 18, 158.	6.8	12
18	Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial. Cardiovascular Drugs and Therapy, 2018, 32, 73-80.	2.6	20

SHINICHIRIO UEDA

#	Article	IF	CITATIONS
19	Longitudinal association among endothelial function, arterial stiffness and subclinical organ damage in hypertension. International Journal of Cardiology, 2018, 253, 161-166.	1.7	51
20	The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1002051.	8.4	57
21	Rationale and design of a multicenter randomized study for evaluating vascular function under uric acid control using the xanthine oxidase inhibitor, febuxostat: the PRIZE study. Cardiovascular Diabetology, 2016, 15, 87.	6.8	28